Industry Segment: Market Brief | Word Count: 138 Words
Attachment: institute

The Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos (Institute of Technology in Immunobiology Bio-Manguinhos) in Brazil started, in August, construction of a 200,000-square-meter New Final Processing Center, to host the so-called Cibs (Complexo Industrial de Biotecnologia em Saude, or Industrial Complex of Biotechnology for Health) in Santa Cruz, Rio de Janeiro, Brazil. Once the project is completed in 2023, the facility is expected to produce 120 million vials per year of vaccines for meningitis, hepatitis, and triple bacterial infections.